SE8505922D0 - Construction of an igg binding protein to facilitate downstream processing using protein engineering - Google Patents

Construction of an igg binding protein to facilitate downstream processing using protein engineering

Info

Publication number
SE8505922D0
SE8505922D0 SE8505922A SE8505922A SE8505922D0 SE 8505922 D0 SE8505922 D0 SE 8505922D0 SE 8505922 A SE8505922 A SE 8505922A SE 8505922 A SE8505922 A SE 8505922A SE 8505922 D0 SE8505922 D0 SE 8505922D0
Authority
SE
Sweden
Prior art keywords
recombinant dna
protein
sequence
fragment
dna molecule
Prior art date
Application number
SE8505922A
Other languages
English (en)
Swedish (sv)
Inventor
L Abrahamsen
T Moks
B Nilsson
M Uhlen
Original Assignee
Kabigen Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of SE8505922D0 publication Critical patent/SE8505922D0/xx
Priority to SE8505922A priority Critical patent/SE8505922D0/xx
Application filed by Kabigen Ab filed Critical Kabigen Ab
Priority to DE8686850416T priority patent/DE3686646T2/de
Priority to ES198686850416T priority patent/ES2046177T3/es
Priority to AT86850416T priority patent/ATE80180T1/de
Priority to EP86850416A priority patent/EP0230869B1/en
Priority to AU66331/86A priority patent/AU600244B2/en
Priority to DK600486A priority patent/DK600486A/da
Priority to JP61296509A priority patent/JPH0811069B2/ja
Priority to CA000525167A priority patent/CA1311430C/en
Priority to US07/594,564 priority patent/US5143844A/en
Priority to GR920402499T priority patent/GR3006178T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SE8505922A 1985-12-13 1985-12-13 Construction of an igg binding protein to facilitate downstream processing using protein engineering SE8505922D0 (sv)

Priority Applications (11)

Application Number Priority Date Filing Date Title
SE8505922A SE8505922D0 (sv) 1985-12-13 1985-12-13 Construction of an igg binding protein to facilitate downstream processing using protein engineering
DE8686850416T DE3686646T2 (de) 1985-12-13 1986-12-02 Herstellung eines igg-bindenden proteins zum erleichtern der weiterverarbeitung mittels "protein-engineering".
ES198686850416T ES2046177T3 (es) 1985-12-13 1986-12-02 Construccion de una proteina enlazante a igg para facilitar el tratamiento aguas abajo utilizando ingenieria de proteinas.
AT86850416T ATE80180T1 (de) 1985-12-13 1986-12-02 Herstellung eines igg-bindenden proteins zum erleichtern der weiterverarbeitung mittels ''protein-engineering''.
EP86850416A EP0230869B1 (en) 1985-12-13 1986-12-02 Construction of an igg binding protein to facilitate downstream processing using protein engineering
AU66331/86A AU600244B2 (en) 1985-12-13 1986-12-09 Construction of an IgG binding protein to facilitate downstream processing using protein engineering
CA000525167A CA1311430C (en) 1985-12-13 1986-12-12 Construction of an igg binding protein to facilitate downstream processing using protein engineering
DK600486A DK600486A (da) 1985-12-13 1986-12-12 Igg-bindingsprotein
JP61296509A JPH0811069B2 (ja) 1985-12-13 1986-12-12 蛋白質工学を用いるダウンストリ−ムプロセツシングを促進するためのＩｇＧ結合性蛋白質の構成
US07/594,564 US5143844A (en) 1985-12-13 1990-10-09 Construction of an igg binding protein to facilitate downstream processing using protein engineering
GR920402499T GR3006178T3 (en, 2012) 1985-12-13 1992-11-05

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8505922A SE8505922D0 (sv) 1985-12-13 1985-12-13 Construction of an igg binding protein to facilitate downstream processing using protein engineering

Publications (1)

Publication Number Publication Date
SE8505922D0 true SE8505922D0 (sv) 1985-12-13

Family

ID=20362468

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8505922A SE8505922D0 (sv) 1985-12-13 1985-12-13 Construction of an igg binding protein to facilitate downstream processing using protein engineering

Country Status (11)

Country Link
US (1) US5143844A (en, 2012)
EP (1) EP0230869B1 (en, 2012)
JP (1) JPH0811069B2 (en, 2012)
AT (1) ATE80180T1 (en, 2012)
AU (1) AU600244B2 (en, 2012)
CA (1) CA1311430C (en, 2012)
DE (1) DE3686646T2 (en, 2012)
DK (1) DK600486A (en, 2012)
ES (1) ES2046177T3 (en, 2012)
GR (1) GR3006178T3 (en, 2012)
SE (1) SE8505922D0 (en, 2012)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK528285D0 (da) * 1985-11-15 1985-11-15 Novo Industri As Peptider samt praeparater indeholdende disse
SE8505921D0 (sv) * 1985-12-13 1985-12-13 Kabigen Ab A method to export gene products to the growth medium of gram negative bacteria
SE8601940D0 (sv) * 1986-04-25 1986-04-25 Kabigen Ab Preparation of fused proteins, antibodies and processes therefor
US5985599A (en) * 1986-05-29 1999-11-16 The Austin Research Institute FC receptor for immunoglobulin
WO1988009344A1 (en) * 1987-05-21 1988-12-01 Creative Biomolecules, Inc. Targeted multifunctional proteins
US5095096A (en) * 1987-05-29 1992-03-10 Sagami Chemical Research Center Fused protein comprising lymphotoxin
US5243040A (en) * 1987-11-20 1993-09-07 Creative Biomolecules DNA encoding a protein which enables selective removal of immune complexes
AU623361B2 (en) * 1987-11-20 1992-05-14 Creative Biomolecules, Inc. Selective removal of immune complexes
US5084398A (en) * 1987-11-20 1992-01-28 Creative Biomolecules Selective removal of immune complexes
SE8800981D0 (sv) * 1988-03-17 1988-03-17 Nygren Per Ake A recombinant fusion protein, its use and a recombinant vector
SE509359C2 (sv) * 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
GB8927008D0 (en) * 1989-11-29 1990-01-17 Ciba Geigy Novel process for the production of unfused protein in e.coli
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5595887A (en) * 1990-07-16 1997-01-21 Bionebraska, Inc. Purification directed cloning of peptides using carbonic anhydrase as the affinity binding segment
US6077694A (en) * 1990-09-21 2000-06-20 The United States Of America As Represented By The Department Of Health And Human Services Method for over-expression and rapid purification of biosynthetic proteins
US5863783A (en) * 1991-03-27 1999-01-26 Gist-Brocades, N.V. Cloning and expression of DNA molecules encoding arabinan-degrading enzymes of fungal origin
US5736363A (en) * 1991-07-29 1998-04-07 British Bio-Technology Limited IGF-II analogues
US5989887A (en) * 1992-11-25 1999-11-23 Dsm N.V. Cloning and expression of DNA molecules incoding arabinan-degrading enzymes of fungal origin
SE9504019D0 (sv) * 1995-11-13 1995-11-13 Pharmacia Ab Method for production of proteins
US5917026A (en) * 1996-02-05 1999-06-29 Loewenadler; Bjoern Fusion proteins of immunopotentiating activity
US5962270A (en) 1996-02-06 1999-10-05 Bionebraska, Inc. Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs
CA2265972A1 (en) * 1996-09-16 1998-03-26 Philip D. Acott Use of igf-i for the treatment of polycystic kidney disease and related indications
US6593290B1 (en) 1996-11-01 2003-07-15 Genentech, Inc. Treatment of inner ear hair cells
US6156728A (en) * 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
CA2356257C (en) 1999-01-06 2012-10-16 Genentech, Inc. Insulin-like growth factor (igf) i mutant variants
IL143866A0 (en) 1999-01-06 2002-04-21 Genentech Inc Insulin-like growth factor (igf) i mutant variants
ES2208305T3 (es) 1999-04-08 2004-06-16 Genentech, Inc. Composicion basada en polipeptidos de carga opuesta..
ATE389416T1 (de) 2000-05-16 2008-04-15 Genentech Inc Behandlung von knorpelerkrankungen
US20030157561A1 (en) * 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
SE0200943D0 (sv) 2002-03-25 2002-03-25 Amersham Biosciences Ab Mutant protein
US20050003548A1 (en) * 2002-07-22 2005-01-06 Nikolay Korokhov Targeted adenoviral vector displaying immunoglobulin-binding domain and uses thereof
HUE027218T2 (en) 2003-09-12 2016-10-28 Ipsen Biopharmaceuticals Inc Methods for Treatment of IGF-1 (Insulin-like Growth Factor 1) Deficiency
EP1670822A2 (en) 2003-10-03 2006-06-21 Genentech, Inc. Igf binding proteins
EP2380594B1 (en) 2004-04-06 2019-12-04 Affibody AB Use of a serum albumin binding peptide to reduce the immunogenicity of a protein
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
JP5808070B2 (ja) 2005-12-02 2015-11-10 ジェネンテック， インコーポレイテッド 結合ポリペプチド及びその使用
JP2008048607A (ja) 2006-08-22 2008-03-06 Chisso Corp Ｆｃ結合ドメインとカルシウム結合発光蛋白質との融合蛋白質、それをコードする遺伝子およびそれらの用途
GB2442118B (en) 2006-09-19 2011-08-17 Chisso Corp Process for production of recombinant proteins as a soluble form
US7691608B2 (en) 2006-12-06 2010-04-06 Repligen Corporation Nucleic acids encoding recombinant protein A
US8198043B2 (en) 2006-12-08 2012-06-12 General Electric Company Two helix binders
US8592555B2 (en) 2008-08-11 2013-11-26 Emd Millipore Corporation Immunoglobulin-binding proteins with improved specificity
SG162687A1 (en) 2008-12-24 2010-07-29 Millipore Corp Caustic stable chromatography ligands
WO2010110288A1 (ja) 2009-03-24 2010-09-30 株式会社カネカ 免疫グロブリンに親和性を有するタンパク質および免疫グロブリン結合性アフィニティーリガンド
EP2414391B1 (en) 2009-04-02 2018-11-28 Roche Glycart AG Multispecific antibodies comprising full length antibodies and single chain fab fragments
CA2781519A1 (en) 2009-09-16 2011-03-24 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
CN107686513A (zh) * 2010-03-08 2018-02-13 通用电气医疗集团生物工艺研发股份公司 免疫球蛋白G Fc区结合多肽
SG184184A1 (en) 2010-03-24 2012-10-30 Kaneka Corp Protein capable of binding specifically to immunoglobulin, and immunoglobulin-binding affinity ligand
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
MX346731B (es) 2010-04-23 2017-03-30 Genentech Inc * Producción de proteínas heteromultiméricas.
MX2013001267A (es) 2010-08-13 2013-04-10 Genentech Inc ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD.
CA2807278A1 (en) 2010-08-24 2012-03-01 F. Hoffmann - La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
US9187555B2 (en) 2010-12-20 2015-11-17 Ge Healthcare Bio-Sciences Ab Affinity chromatography matrix
JP5974342B2 (ja) 2010-12-20 2016-08-23 ジーイー・ヘルスケア・バイオプロセス・アールアンドディ・アクチボラグ アフィニティークロマトグラフィーマトリックス
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
AR085138A1 (es) 2011-02-04 2013-09-11 Genentech Inc VARIANTES DE Fc Y METODOS PARA SU PRODUCCION
SG193950A1 (en) * 2011-03-25 2013-11-29 Kaneka Corp Novel immunoglobulin-binding polypeptide
SG10201604554WA (en) 2011-06-08 2016-07-28 Emd Millipore Corp Chromatography matrices including novel staphylococcus aureus protein a based ligands
MX359384B (es) 2011-10-11 2018-09-25 Genentech Inc Conjunto mejorado de anticuerpos bisespecificos.
RU2644341C2 (ru) 2012-02-10 2018-02-08 Дженентек, Инк. Одноцепочечные антитела и другие гетеромультимеры
WO2013147691A1 (en) 2012-03-28 2013-10-03 Ge Healthcare Bio-Sciences Ab Affinity chromatography matrix
HK1207864A1 (en) 2012-06-27 2016-02-12 F. Hoffmann-La Roche Ag Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
WO2014001325A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
CN105377880B (zh) 2013-07-10 2020-08-07 通用电气医疗集团生物工艺研发股份公司 突变的免疫球蛋白结合多肽
JP6491600B2 (ja) 2013-09-27 2019-03-27 株式会社カネカ アルカリ水溶液を用いた多孔質セルロースビーズの製造方法
HRP20231139T1 (hr) 2014-05-06 2024-01-05 F. Hoffmann - La Roche Ag Proizvodnja heteromultimernih proteina upotrebom stanica sisavaca
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
JP6721590B2 (ja) 2014-12-03 2020-07-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性抗体
WO2016121703A1 (ja) 2015-01-26 2016-08-04 株式会社カネカ 変異型免疫グロブリンκ鎖可変領域結合性ペプチド
WO2016121701A1 (ja) 2015-01-26 2016-08-04 株式会社カネカ 免疫グロブリンκ鎖可変領域含有タンパク質精製用アフィニティー分離マトリックス
JP6424101B2 (ja) * 2015-01-30 2018-11-14 Jnc株式会社 Ｆｃ結合ドメインとカルシウム結合発光蛋白質との融合蛋白質、それをコードする遺伝子およびそれらの用途
KR20170115535A (ko) 2015-02-05 2017-10-17 미쯔비시 케미컬 주식회사 면역 글로불린에 친화성을 갖는 단백질, 및 그것을 사용한 친화성 분리제, 액체 크로마토그래피용 칼럼
WO2017195638A1 (ja) 2016-05-09 2017-11-16 株式会社カネカ 抗体またはκ鎖可変領域含有抗体断片の精製方法
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
EP3455240B1 (en) 2016-05-11 2025-01-01 Cytiva BioProcess R&D AB Method of storing a separation matrix
JP6987424B2 (ja) 2016-05-11 2022-01-05 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックスを洗浄および／または消毒する方法
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
EP3455243B1 (en) 2016-05-11 2021-03-24 Cytiva BioProcess R&D AB Separation matrix
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US11779860B2 (en) 2017-08-07 2023-10-10 Repligen Corporation Fc binding proteins with cysteine in the C-terminal helical region
EP4249097A3 (en) 2018-02-01 2024-01-10 Repligen Corporation Fc binding proteins with cysteine in the c-terminal helical region
GB202018588D0 (en) 2020-11-26 2021-01-13 Cytiva Bioprocess R & D Ab Separation matrix
GB202113626D0 (en) 2021-09-24 2021-11-10 Cytiva Bioprocess R & D Ab FC binding polypeptides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769326A (en) * 1980-02-29 1988-09-06 The Regents Of The University Of California Expression linkers
SE8300693L (sv) * 1983-02-09 1984-08-10 Sven Lofdahl Sett att framstella och isolera proteiner och polypeptider samt en hybridvektor for detta

Also Published As

Publication number Publication date
JPS62190087A (ja) 1987-08-20
EP0230869A2 (en) 1987-08-05
AU6633186A (en) 1987-06-18
DE3686646T2 (de) 1993-04-08
EP0230869A3 (en) 1988-08-03
US5143844A (en) 1992-09-01
AU600244B2 (en) 1990-08-09
JPH0811069B2 (ja) 1996-02-07
CA1311430C (en) 1992-12-15
EP0230869B1 (en) 1992-09-02
DE3686646D1 (de) 1992-10-08
DK600486D0 (da) 1986-12-12
ATE80180T1 (de) 1992-09-15
GR3006178T3 (en, 2012) 1993-06-21
DK600486A (da) 1987-06-14
ES2046177T3 (es) 1994-02-01

Similar Documents

Publication Publication Date Title
SE8505922D0 (sv) Construction of an igg binding protein to facilitate downstream processing using protein engineering
Gundelfinger et al. The organization of the 7SL RNA in the signal recognition particle
BR9610511A (pt) Molécula de dna de forma circular útil em terapia gênica compreendendo ao menos uma sequência nucléica de interesse processo para sua produção célula recombinante composição farmacêutica utilização de uma molécula de dna e processo de produção de uma proteína recombinante
IL57491A (en) Recombinant dna,methods for the production thereof and proteins or polypeptides produced thereby
ZA822855B (en) Bacillus cloning vectors,recombinant dna molecules,bacillus hosts transformed with them and methods for expressing foreign dna sequences and producing polypeptides coded thereby
WO1995016048A3 (en) Recombinant protein production in bovine adenovirus expression vector system
ATE242808T1 (de) Cytoplasmatische expression von antikörpern, antikörperfragmenten und antikörperfragment- fusionsmolekülen in e. coli
Johnson et al. Identification of a plastid-specific ribosomal protein in the 30 S subunit of chloroplast ribosomes and isolation of the cDNA clone encoding its cytoplasmic precursor.
JPS6420095A (en) Polypeptide having anti-blood coagulating action
HUT52551A (en) Process for production of neutrophil-activizating factor
IL99079A0 (en) Protein structure of the plant toxin gelonin
DK0805204T3 (da) Bitestikel - specifikt receptorprotein og anvendelse heraf
Roberts et al. Different active sites of mammalian DNA ligases I and II.
DE3572843D1 (en) Site-specific proteolysis by renin
Boyle et al. All major regions of FtsK are required for resolution of chromosome dimers
DE69634757D1 (de) Vektor zur expression von n-terminal verlängerten proteinen in hefezellen
Taylor et al. Similarities in the heavy and light chains of tetanus toxin suggested by their amino acid compositions
Bolyard et al. Expression in Escherichia coli of the human fibrinogen B beta chain and its cleavage by thrombin
Thomann et al. Homologous expression and purification of mutants of an essential protein by reverse epitope-tagging
Ikeuchi et al. The enhancing of a cysteine proteinase activity at acidic pH by protein engineering, the role of glutamic 50 in the enzyme mechanism of caricain
EP0688224A4 (en) MUTANT PROTEIN, METHODS AND MATERIALS USED FOR ITS MANUFACTURE AND USE
JPH07163379A (ja) シグナル配列ペプチドをコードするｄｎａ断片の探索法及びそのためのベクター
Troitskiĭ et al. Purification, heterogeneity and some properties of T2 bacteriophage lysozyme
Stefani Mapping the Transcriptional Unit of the Human Epsilon Globin Gene
TW287199B (en) A method for genetically producing a protein exhibiting the activity of epstein-barr virus DNA polymerase